Intercept Pharma

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Intercept Pharma reports robust earnings, eyes growth amid competitive challenges

Intercept Pharma's Q4 2022 earnings call highlighted strong financial performance, strategic advancements, and a focus on innovation and market expansion.
The company's achievements in sales growth, patent protection, and financial stability position it well for future growth and leadership in the PBC and NASH markets.
Challenges in competitive dynamics and regulatory landscape require proactive strategies, while opportunities in new programs and market developments offer avenues for continued success.
Overall, Intercept Pharma's performance underscores a resilient and forward-thinking approach to navigating the complexities of the pharmaceutical industry and driving sustainable growth.

Intercept Pharma reports growth in sales and navigates NASH landscape

Intercept Pharma's Q1 2023 performance saw growth in net sales and strong sales performance of OCALIVA.
The company's focus on F3-like NASH patients and competitive positioning of OCA are key strengths.
Challenges include pricing strategy discussions and questions on combination approaches.
Opportunities lie in addressing AdCom discussions, expanding prescriber base, and preventing cirrhosis progression.

Intercept Pharma reports strong Q2 earnings, eyes FDA relations

Intercept Pharma's strong performance in Q2 2023 shows progress towards profitability by 2024. The company is addressing challenges in FDA relations and study enrollments while leveraging market opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases.

B. Riley upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Neutral with a price target of $30, up from $25.  Analyst Mayank Mamtani sees a "catalyst rich" 1H of 2022 for the Company.

B. Riley Beefs Up Intercept Target Price On Catalyst Rich 1H 2022

Alnylam Pharmaceuticals

Karuna Therapeutics Inc

This could be a very exciting year for these drugmakers.

3 Can't-Miss Biotech Events Coming Up in 2022

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05377, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Intercept securities between September 28, 2019 and October 7, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action against Intercept Pharmaceuticals, Inc. and Certain Officers - ICPT

Madrigal Pharmaceuticals

Novavax

Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.

3 Biotech Stocks With Major Catalysts in January

Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the year Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the year

Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH

Biofrontera

Blink Charging

Cortexyme Inc

Longeveron

Lemonade

Prelude Therapeutics

Reliance Global Group

Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec. 17 appeared first on InvestorPlace.

The 10 Most Shorted Stocks Right Now for Friday, Dec. 17

The stock price of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) fell by 6.45% this past week. This is why it happened.

Intercept Pharmaceuticals Stock (ICPT): Why The Price Fell This Week

Investors need to pay close attention to Intercept (ICPT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Intercept (ICPT) Stock?

Intercept (ICPT) withdraws its application seeking approval for OCA for the treatment of liver fibrosis due to nonalcoholic steatohepatitis in the EU. Resultantly, the stock declines.

Intercept (ICPT) Down on Withdrawal of Application for NASH

The stock price of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) fell by 14.87% today. This is why it happened.

Intercept Pharmaceuticals Stock (ICPT): Why The Price Fell Today

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has withdrawn its European marketing application seeking approval for obeticholic acid (OCA) for liver fibrosis due to nonalcoholic steatohepatitis (NASH). The initial application was filed in December 2019 was supported by the interim analysis results from the Phase 3 REGENERATE study, which remains ongoing.

Why Are Intercept Pharmaceuticals Shares Falling Today?

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has formally notified the European Medicines Agency (EMA) of its decision to withdraw its Marketing Authorization Application (MAA) for obeticholic acid (OCA) for the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH).

Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

Intercept (ICPT) Down 10.7% Since Last Earnings Report: Can It Rebound?

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has announced results from a new analysis examining obeticholic acid's (OCA) potential to improve transplant-free survival in patients with primary biliary cholangitis (PBC). In the analysis, 209 patients treated with OCA in the POISE long-term safety extension study had significantly greater transplant-free survival than patients in the external control groups.

Intercept Posts Long-Term Data For Obeticholic Acid In Chronic Liver Disease Patients

Analysis compares findings from the long-term safety extension of the Phase 3 POISE trial to PBC natural history data from the Global PBC and UK-PBC databases

Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC

NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept; M. Michelle Berrey, M.D., M.P.H., President of Research & Development and Chief Medical Officer of Intercept; Linda Richardson, Chief Commercial Officer of Intercept; and Andrew Saik, Chief Financial Officer of Intercept, will participate virtually in fireside chats at the following upcoming investor conferences:

Intercept to Present at Upcoming Investor Conferences

Intercept (ICPT) posts a narrower loss in the third quarter and sales beat estimates.

Intercept (ICPT) Beats on Q3 Earnings & Sales, Ups View

Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q3 2021 Results - Earnings Call Transcript

Worldwide Ocaliva® net sales of $92.8 million, representing 17% growth over the prior year quarter

Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

CRISPR Therapeutics

Ligand Pharmaceuticals

Vaxart

Based on analysts' loftiest price targets, these drugmakers could double to nearly quintuple investors' money over the next 12 months.

5 Biotech Stocks With 105% to 386% Upside, According to Wall Street

Late-breaking oral presentation compares transplant-free survival in patients with PBC treated with OCA to external controls from the Global PBC and UK-PBC study groups

Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting

Philadelphia, Pennsylvania--(Newsfile Corp. - October 23, 2021) - Kaskela Law LLC announces that it is investigating Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) on behalf of the Company's stockholders.Recently an amended securities fraud complaint was filed against Intercept on behalf of investors who purchased shares of Intercept's common stock between September 27, 2019 and October 8, 2020. According to the complaint, during that time period Intercept and certain senior executive officers...

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) and Encourages Long-Term ICPT Stockholders to Contact the Firm

The mean of analysts' price targets for Intercept (ICPT) points to a 94.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Intercept (ICPT) Could Surge 95%: Read This Before Placing a Bet

Big 5 Sporting Goods

Corsair Gaming

FuboTV

GoodRx Holdings

PetMed Express

Meme stocks are seeing a sudden increase in volume and price. Here are seven of the best meme stocks to buy.

7 Meme Stocks With Short-Squeeze Potential In October

Arcimoto

Greenidge Generation Holdings

iRobot

Lordstown Motors

SmileDirectClub

Workhorse Group

While betting on short-interest stocks has become a popular speculation tactic, you want to be careful about this fad. The post 7 Short-Interest Stocks That Could Be Bull Traps appeared first on InvestorPlace.

News for Intercept Pharma Stock (ICPT)